PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of α-momorcharin in vivo

References

• Leung, K.C., Meng, Z.Q., Ho, W.K. Antigenic determination fragments of α-momorcharin. Biochim Biophys Acta 1997, 1336, 419–424.
   PubMed Web of Science ®Google Scholar
• Ng, T.B., Liu, W.K., Sze, S.F., Yeung, H.W. Action of α-momorcharin, a ribosome inactivating protein, on cultured tumor cell lines. Gen Pharmacol 1994, 25, 75–77.
   PubMedGoogle Scholar
• Zhang, L.L., Ding, Q., Zhan, J.B. [Expression of recombinant ribosome inactivating protein MAP30 in E.coli and its biological activity]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2010, 39, 264–271.
   Google Scholar
• Zheng, Y.T., Ben, K.L., Jin, S.W. α-momorcharin inhibits HIV-1 replication in acutely but not chronically infected T-lymphocytes. Zhongguo Yao Li Xue Bao 1999, 20, 239–243.
   PubMed Web of Science ®Google Scholar
• Pasut, G., Veronese, F.M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009, 61, 1177–1188.
   PubMed Web of Science ®Google Scholar
• Soderquist, R.G., Milligan, E.D., Sloane, E.M., Harrison, J.A., Douvas, K.K., Potter, J.M., Hughes, T.S., Chavez, R.A., Johnson, K., Watkins, L.R., Mahoney, M.J. PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J Biomed Mater Res A 2009, 91, 719–729.
   PubMedGoogle Scholar
• Sugiyama, A., Sato, A., Takeuchi, T. PEGylated lactoferrin enhanced its hepatoprotective effects on acute liver injury induced by carbon tetrachloride in rats. Food Chem Toxicol 2009, 47, 1453–1458.
   PubMed Web of Science ®Google Scholar
• Tsui, S.M., Lam, W.M., Lam, T.L., Chong, H.C., So, P.K., Kwok, S.Y., Arnold, S., Cheng, P.N., Wheatley, D.N., Lo, W.H., Leung, Y.C. PEGylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). Cancer Cell Int 2009, 9, 9.
   Google Scholar
• Li, M., Chen, Y., Liu, Z., Shen, F., Bian, X., Meng, Y. Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol. Acta biochimica et biophysica Sinica 2009, 41, 792–799.
   PubMed Web of Science ®Google Scholar
• Bian, X., Shen, F., Chen, Y., Wang, B., Deng, M., Meng, Y. PEGylation of α-momorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potential. Biotechnology letters 2010, 32, 883–890.
   PubMed Web of Science ®Google Scholar
• Zheng, S.S., Wai, W.L., Hin, W.Y., Wu, A.R. Kinetics of IgE antibody response to trichosanthin α-momorcharin and β-momorcharin in mice. Chin Med J 1991, 104, 292–299.
   Google Scholar
• Cohen, S., Dworetzky, M., Frick, O.L. Coca and Cooke on the classification of hypersensitiveness. J Allergy Clin Immunol 2003, 111, 205–210.
   Google Scholar
• Marone, P.A., Yasmin, T., Gupta, R.C., Bagchi, M. Safety and toxicological evaluation of AlgaeCal (AC), a novel plant-based calcium supplement. Toxicol Mech Methods 2010, 20, 334–344.
   PubMed Web of Science ®Google Scholar
• Sreejayan, N., Marone, P.A., Lau, F.C., Yasmin, T., Bagchi, M., Bagchi, D. Safety and toxicological evaluation of a novel chromium(III) dinicocysteinate complex. Toxicol Mech Methods 2010, 20, 321–333.
   PubMed Web of Science ®Google Scholar
• Chapman, A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002, 54, 531–545.
   PubMed Web of Science ®Google Scholar
• Chua, C.C., Greenberg, M.L., Viau, A.T., Nucci, M., Brenckman, W.D. Jr, Hershfield, M.S. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 1988, 109, 114–117.
   PubMedGoogle Scholar
• Duncan, R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2, 347–360.
   PubMed Web of Science ®Google Scholar
• Fee, C.J. Size-exclusion reaction chromatography (SERC): a new technique for protein PEGylation. Biotechnol Bioeng 2003, 82, 200–206.
   PubMed Web of Science ®Google Scholar
• Foster, G.R. Review article: PEGylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004, 20, 825–830.
   PubMed Web of Science ®Google Scholar
• Hinds, K.D., Kim, S.W. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 2002, 54, 505–530.
   PubMed Web of Science ®Google Scholar
• Sundy, J.S., Ganson, N.J., Kelly, S.J., Scarlett, E.L., Rehrig, C.D., Huang, W., Hershfield, M.S. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56, 1021–1028.
   PubMed Web of Science ®Google Scholar
• Veronese, F.M., Harris, J.M. Introduction and overview of peptide and protein PEGylation. Adv Drug Deliv Rev 2002, 54, 453–456.
   PubMed Web of Science ®Google Scholar
• Veronese, F.M., Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10, 1451–1458.
   PubMed Web of Science ®Google Scholar
• Ryan, S.M., Mantovani, G., Wang, X., Haddleton, D.M., Brayden, D.J. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 2008, 5, 371–383.
   PubMed Web of Science ®Google Scholar
• Chan, W.L., Shaw, P.C., Tam, S.C., Jacobsen, C., Gliemann, J., Nielsen, M.S. Trichosanthin interacts with and enters cells via LDL receptor family members. Biochem Biophys Res Commun 2000, 270, 453–457.
   Google Scholar
• Chan, W.Y., Huang, H., Tam, S.C. Receptor-mediated endocytosis of trichosanthin in choriocarcinoma cells. Toxicology 2003, 186, 191–203.
   Google Scholar
• Zheng, G., Bachinsky, D.R., Stamenkovic, I., Strickland, D.K., Brown, D., Andres, G., McCluskey, R.T. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/α 2MR, and the receptor-associated protein (RAP). J Histochem Cytochem 1994, 42, 531–542.
   PubMedGoogle Scholar